Loading…
Reported covered position: Legislative Director, Rep. Eric Cantor
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Medicare Part D phase-in of manufacturer liability H.R 1476 PLASMA Act
Medicare Part D phase-in of manufacturer liability; Issues related to Medicare Most Favored Nation H.R 1476 PLASMA Act
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
CSL BEHRING LLC via CSL BEHRING LLC
2026 · third_quarter · Q3
Medicare Part D phase-in of manufacturer liability H.R 1476 PLASMA Act
Issues related to trade
Issues related to corporate tax
Source: Senate LDA
HR 1476--Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act)--Medicare Part D phase-in of manufacturer liability; Issues related to Medicare Most Favored Nation
HR 1476--Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act)--Medicare Part D phase-in of manufacturer liability
HR 1476--Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act)--Medicare Part D phase-in of manufacturer liability; Medicare/Medicaid Most Favored Nation
HR 1476--Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act)--Medicare Part D phase-in of manufacturer liability; Issues related to Medicare Most Favored Nation
Education regarding H.R.6465-Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act) Issues related to the Medicaid Drug Rebate Program proposed rule, gene therapies, and value-based payment arrangements. Education on issues related to plasma derived products and inflation penalties related to drug shortages. Education on tax policies specific to the biopharmaceutical industry.
Education regarding H.R.6465-Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act) Issues related to the Medicaid Drug Rebate Program proposed rule, gene therapies, and value-based payment arrangements. Education on issues related to plasma derived products and inflation penalties related to drug shortages. Education on tax policies specific to the biopharmaceutical industry.
Education regarding H.R.6465-Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act) Issues related to the Medicaid Drug Rebate Program proposed rule, gene therapies, and value-based payment arrangements. Education on issues related to plasma derived products and inflation penalties related to drug shortages.
Education regarding H.R.6465-Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act) Issues related to the Medicaid Drug Rebate Program proposed rule, gene therapies, and value-based payment arrangements. Education on issues related to plasma derived products and inflation penalties related to drug shortages.
Education regarding H.R.6465-Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act) Issues related to the Medicaid Drug Rebate Program proposed rule, gene therapies, and value-based payment arrangements. Education on issues related to plasma derived products and inflation penalties related to drug shortages.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CSL BEHRING LLC via CSL BEHRING LLC
2026 · second_quarter · Q2
Issues related to trade
Medicare Part D phase-in of manufacturer liability; Issues related to Medicare Most Favored Nation H.R 1476 PLASMA Act
Issues related to corporate tax
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CSL BEHRING LLC via CSL BEHRING LLC
2026 · first_quarter · Q1
Issues related to corporate tax
Issues related to trade
Medicare Part D phase-in of manufacturer liability; Issues related to Medicare Most Favored Nation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CSL BEHRING LLC via CSL BEHRING LLC
2025 · fourth_quarter · Q4
Issues related to corporate tax
Issues related to trade
HR 1476--Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act)--Medicare Part D phase-in of manufacturer liability; Issues related to Medicare Most Favored Nation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CSL BEHRING LLC via CSL BEHRING LLC
2025 · third_quarter · Q3
HR 1476--Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act)--Medicare Part D phase-in of manufacturer liability; Issues related to Medicare Most Favored Nation
Issues related to corporate tax
Issues related to trade
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CSL BEHRING LLC via CSL BEHRING LLC
2025 · second_quarter · Q2
HR 1476--Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act)--Medicare Part D phase-in of manufacturer liability; Medicare/Medicaid Most Favored Nation
Issues related to corporate tax
Issues related to trade
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CSL BEHRING LLC via CSL BEHRING LLC
2025 · first_quarter · Q1
HR 1476--Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act)--Medicare Part D phase-in of manufacturer liability
Issues related to corporate tax
Issues related to trade
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CSL BEHRING LLC via CSL BEHRING LLC
2024 · fourth_quarter · Q4
Education regarding H.R.6465-Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act) Issues related to the Medicaid Drug Rebate Program proposed rule, gene therapies, and value-based payment arrangements. Education on issues related to plasma derived products and inflation penalties related to drug shortages. Education on tax policies specific to the biopharmaceutical industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CSL BEHRING LLC via CSL BEHRING LLC
2024 · third_quarter · Q3
Education regarding H.R.6465-Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act) Issues related to the Medicaid Drug Rebate Program proposed rule, gene therapies, and value-based payment arrangements. Education on issues related to plasma derived products and inflation penalties related to drug shortages. Education on tax policies specific to the biopharmaceutical industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CSL BEHRING LLC via CSL BEHRING LLC
2024 · second_quarter · Q2
Education regarding H.R.6465-Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act) Issues related to the Medicaid Drug Rebate Program proposed rule, gene therapies, and value-based payment arrangements. Education on issues related to plasma derived products and inflation penalties related to drug shortages.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CSL BEHRING LLC via CSL BEHRING LLC
2024 · first_quarter · Q1
Education regarding H.R.6465-Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act) Issues related to the Medicaid Drug Rebate Program proposed rule, gene therapies, and value-based payment arrangements. Education on issues related to plasma derived products and inflation penalties related to drug shortages.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CSL BEHRING LLC via CSL BEHRING LLC
2023 · fourth_quarter · 4A
Education regarding H.R.6465-Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act) Issues related to the Medicaid Drug Rebate Program proposed rule, gene therapies, and value-based payment arrangements. Education on issues related to plasma derived products and inflation penalties related to drug shortages.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CSL BEHRING LLC via CSL BEHRING LLC
2023 · fourth_quarter · Q4
Education regarding the Inflation Reduction Act Medicare Part D Redesign and Inflation Penalties Issues related to the Medicaid Drug Rebate Program proposed rule, gene therapies, and value-based payment arrangements. Education on issues related to plasma derived products and drug shortages.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CSL BEHRING LLC via CSL BEHRING LLC
2023 · third_quarter · Q3
Education regarding the Inflation Reduction Act Medicare Part D Redesign and Inflation Penalties
Filing targets: HOUSE OF REPRESENTATIVES, SENATE